The decision by the Therapeutic Goods Administration (TGA) of Australia allows for the use of psilocybin – a naturally occurring psychedelic compound found in certain types of mushrooms – for the treatment of certain mental health conditions.
In addition the Therapeutic Goods Administration,Australia’s drug watchdog approved the move following a three year process which included extensive consultation with the experts.
However this move comes after a growing body of research has shown promising results in using psychedelics to treat depression, anxiety, addiction, and PTSD.
In fact, several clinical trials have demonstrated that psilocybin can provide significant relief to individuals suffering from treatment-resistant depression and other mental health disorders.
Meanwhile it’s important to note that the use of psychedelics will be limited to approved clinical trials and will only be available to patients under the supervision of a qualified healthcare professional.
This decision by the TGA is a significant step forward in the use of alternative treatments for mental health conditions, and it’s likely that more countries will consider similar measures in the future.
Check also;
- Pfizer Reports Failure Of Paxlovid Treatment To Avoid Family Getting Infected
- Norway Asks People To Keep Distance From Spy Whale To Ensure Animal’s Safety
Please use the button below to contribute to Newslex Point, Inc. using a credit card or via PayPal.